Annals of Oncology Advance Access originally published online on March 17, 2006
Annals of Oncology 2006 17(6):897-907; doi:10.1093/annonc/mdj105
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
review |
Management of the adverse effects associated with intravenous bisphosphonates
1 H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA; 2 Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA
* Correspondence to: Dr T. Tanvetyanon at H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33613, USA. E-mail: tanvett{at}moffitt.usf.edu
Intravenous bisphosphonates are widely used to treat hypercalcemia and to reduce skeletal-related morbidity among cancer patients. However, serious complications, generally occurring in less than 2% of patients participated in phase III clinical trials, including acute systemic inflammatory reaction, ocular inflammation, renal failure, nephrotic syndrome, electrolyte imbalance, and osteonecrosis of the maxilla and mandible have all been increasingly reported. Yet, strategies to deal with these complications are becoming clear. Acute systemic inflammatory reaction is often self-limited and becomes less intense during subsequent treatments. For patients who develop ocular symptoms, prompt ophthalmologic evaluation is crucial to determine the safety of a subsequent bisphosphonate therapy. Patients who receive long-term pamidronate should be evaluated at intervals for early sign of nephritic syndrome as timely cessation of the agent may result in a full recovery. To reduce the risk of severe electrolyte abnormalities, particularly hypocalcemia, correcting any pre-treatment electrolyte abnormality and supplementing vitamin D and calcium may be helpful. Finally, to reduce the risk of osteonecrosis of the maxilla and mandible, obtaining a full dental evaluation before treatment and avoidance of invasive dental procedures is suggested. The three commonly used intravenous bisphosphonates (pamidronate, zoledronic acid, and ibandronate), are generally safe; ibandronate has to date been the least reported to be associated with renal side effects. As clinical indications of intravenous bisphosphonates continue to expand, prescribing clinicians should be familiar with these possible adverse effects and discuss them with patients before commencing or continuing on therapy.
Key words: bisphosphonate, pamidronate, zoledronic acid, clodronate, ibandronate, side effect
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., August 1, 2009; 20(8): 1303 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Olson and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bodmer, P. Amico, M. J. Mihatsch, M. Haschke, O. Kummer, S. Krahenbuhl, and M. Mayr Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2366 - 2370. [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Shenker and A. S. M. Jawad Bisphosphonates and osteonecrosis of the jaw Rheumatology, July 1, 2007; 46(7): 1049 - 1051. [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. M. Durie and IMWG Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement Mayo Clin. Proc., April 1, 2007; 82(4): 516 - 517. [Full Text] [PDF]
|
|
|
|
|
|
D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis Ann. Onc., March 1, 2007; 18(3): 556 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli The Use of Bisphosphonates in Elderly Cancer Patients Oncologist, January 1, 2007; 12(1): 62 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hollander and J. I. Mechanick Nutrition Support and the Chronic Critical Illness Syndrome Nutr Clin Pract, December 1, 2006; 21(6): 587 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Berruti, M Tucci, D Generali, A Mosca, M Ardine, F Vana, and L Dogliotti Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation Ann. Onc., December 1, 2006; 17(12): 1854 - 1855. [Full Text] [PDF]
|
|
|
|
|
|
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al. Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|